[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C@@H1][C@H1][Ring1][Ring1][C@@H1][C][=C][C@H1][Ring1][=Branch1][C@@H1][C@H1][Ring1][=Branch1][C][=Branch1][C][=O][N][Branch1][Branch1][C][Ring1][=Branch1][=O][N][C][=Branch1][C][=O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][Branch1][C][F][Branch1][C][F][F]"}, {"from": "gpt", "value": "The molecule is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses, including vaccinia, cowpox, ectromelia, rabbitpox, monkeypox, and Variola (smallpox) virus.  Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox. Tecovirimat was later approved by Health Canada in December 2021, followed by the approval from the European Commission in January 2022. Other than smallpox, tecovirimat is also indicated to treat complications due to replication of the vaccinia virus following vaccination against smallpox, and to treat monkeypox and cowpox in adults and children. Tecovirimat is available as both oral and intravenous formulations."}]